Highly Sensitive Chemiluminescence-Based Lateral Flow Immunoassay for Cardiac Troponin I Detection in Human Serum

Han, Gyeo-Re; Kim, Min-Gon

doi:10.3390/s20092593

Cited by 36 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More importantly, LOD reached a value as low as 17 pg mL −1 . Compared with other reports related to cTnI determination (Table 1), 13,[37][38][39][40][41][42][43][44][45] the prepared lanthanide-doped NPs-based LFA has the merits of relatively low LOD and wide linear range. As for colorimetry, it is hard to distinguish the intermediate color with the naked eye.…”

Section: Analytical Performance Of Lfa Platformmentioning

confidence: 86%

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Chen¹,

Zhou²,

Zhu³

et al. 2022

IJN

View full text Add to dashboard Cite

Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity. Methods: To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu 3+ -doped vanadate nanoparticles (GdVO 4 :30% Eu NPs) were used as luminescent probes to allow quantification. Results: Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL −1 for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples. Conclusion: Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.

show abstract

Section: Analytical Performance Of Lfa Platformmentioning

confidence: 86%

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Chen¹,

Zhou²,

Zhu³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Han et al proposed a new conjugation scheme for development of high-performance LFIAs [ 77 ]. AuNPs conjugated with aldehyde-activated HRP and antibody molecules (AuNP-(ald)HRP-Ab) were produced and employed in a highly sensitive CL-LFIA for human cardiac troponin I (cTnI), a cardiac biomarker used to diagnose myocardial infarction.…”

Section: Modification Of Mnps Labels With Enzyme: Enhancing Lfia Performancementioning

confidence: 99%

Recent Advancements in Enzyme-Based Lateral Flow Immunoassays

Calabria

Calabretta

Zangheri

et al. 2021

Sensors

View full text Add to dashboard Cite

Paper-based lateral-flow immunoassays (LFIAs) have achieved considerable commercial success and their impact in diagnostics is continuously growing. LFIA results are often obtained by visualizing by the naked eye color changes in given areas, providing a qualitative information about the presence/absence of the target analyte in the sample. However, this platform has the potential to provide ultrasensitive quantitative analysis for several applications. Indeed, LFIA is based on well-established immunological techniques, which have known in the last year great advances due to the combination of highly sensitive tracers, innovative signal amplification strategies and last-generation instrumental detectors. All these available progresses can be applied also to the LFIA platform by adapting them to a portable and miniaturized format. This possibility opens countless strategies for definitively turning the LFIA technique into an ultrasensitive quantitative method. Among the different proposals for achieving this goal, the use of enzyme-based immunoassay is very well known and widespread for routine analysis and it can represent a valid approach for improving LFIA performances. Several examples have been recently reported in literature exploiting enzymes properties and features for obtaining significative advances in this field. In this review, we aim to provide a critical overview of the recent progresses in highly sensitive LFIA detection technologies, involving the exploitation of enzyme-based amplification strategies. The features and applications of the technologies, along with future developments and challenges, are also discussed.

show abstract

“…Its chromogenic substrate, 3,3′,5,5′tetramethylbenzidine (TMB), is being oxidized by HRP in in presence of H 2 O 2 , resulting in a product that is visualized on the LFSs [64]. Apart from detecting colored product, a chemiluminescent (CL) signal can be obtained from the catalytic reaction of luminol with H 2 O 2 via HRP that can be detected by a charged-coupled device (CCD) camera or other analyzer system [65,66]. The high sensitivity and high signal-to-noise ratio using simple optical readout systems make CL more attractive than other optical readout methods.…”

Section: Signal Tracers and Non-electrochemical Readingsmentioning

confidence: 99%

Integrating high-performing electrochemical transducers in lateral flow assay

Perju

Wongkaew

2021

Anal Bioanal Chem

View full text Add to dashboard Cite

Lateral flow assays (LFAs) are the best-performing and best-known point-of-care tests worldwide. Over the last decade, they have experienced an increasing interest by researchers towards improving their analytical performance while maintaining their robust assay platform. Commercially, visual and optical detection strategies dominate, but it is especially the research on integrating electrochemical (EC) approaches that may have a chance to significantly improve an LFA’s performance that is needed in order to detect analytes reliably at lower concentrations than currently possible. In fact, EC-LFAs offer advantages in terms of quantitative determination, low-cost, high sensitivity, and even simple, label-free strategies. Here, the various configurations of EC-LFAs published are summarized and critically evaluated. In short, most of them rely on applying conventional transducers, e.g., screen-printed electrode, to ensure reliability of the assay, and additional advances are afforded by the beneficial features of nanomaterials. It is predicted that these will be further implemented in EC-LFAs as high-performance transducers. Considering the low cost of point-of-care devices, it becomes even more important to also identify strategies that efficiently integrate nanomaterials into EC-LFAs in a high-throughput manner while maintaining their favorable analytical performance.

show abstract

Highly Sensitive Chemiluminescence-Based Lateral Flow Immunoassay for Cardiac Troponin I Detection in Human Serum

Cited by 36 publications

References 24 publications

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Recent Advancements in Enzyme-Based Lateral Flow Immunoassays

Integrating high-performing electrochemical transducers in lateral flow assay

Contact Info

Product

Resources

About